


1644  
*[Signature]*



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor(s):	Ibert C. Wells	)	Examiner:	Szperka, Michael Edward
		)		
Serial No.:	10/053,669	)	Art Unit:	1644
		)		
Filing Date:	January 24, 2002	)		
		)		
Title:	METHOD FOR	)		
	DETECTING DEFICIENT	)		
	CELLULAR MEMBRANE	)		
	TIGHTLY BOUND	)		
	MAGNESIUM FOR	)		
	DISEASE DIAGNOSES	)		

**INFORMATION DISCLOSURE STATEMENT  
WITH CERTIFICATION UNDER 37 C.F.R. § 1.97(c)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. § 1.56 and § 1.97(c), the references listed below and on the attached Form PTO/SB/08A (Substitute for Form 1449A-B/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed. Submission of these references is not an admission that the references constitute prior art.

**Certificate of Mailing Under 37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date: December 10, 2004  
Signature: *Lora Gurley*  
Printed Name: Lora Gurley

The Director is hereby authorized to charge any additional amount required, or credit any overpayment, to Deposit Account No. 19-4409.

**U.S. PATENTS**

<b><u>Patent No.</u></b>	<b><u>Inventor(s)</u></b>	<b><u>Issue Date</u></b>
None		

**FOREIGN PATENTS**

<b><u>Country</u></b>	<b><u>Patent No./Publication No.</u></b>	<b><u>Publication Date</u></b>
None		

**OTHER REFERENCES**

MORI, KAZUO, et al. Decreases in Substance P and Vasoactive Intestinal Peptide Concentrations in Plasma of Stroke-Prone Spontaneously Hypertensive Rats. Jpn. Heart J. 1993, 34:785-794.

SANFILIPPO, JOSEPH S., et al. Amniotic Fluid Levels of Substance P. J. Reprod. Med. 1992, 37:733-736.

FAULHABER, H.D., et al. Substance P in Human Essential Hypertension. J. Cardiovascular Pharmacology, 1987, 10(Suppl. 12):S172-S176.

PAGE, N.M., et al. Excessive Placental Secretion of Neurokinin B During the Third Trimester Causes Pre-eclampsia. Nature 2000, 405:797-800.

Applicant respectfully requests that these references be made of record in the above-identified application and considered by the Examiner during prosecution of the application.

It is respectfully submitted that the present invention as claimed is patentable over the listed references.

This information disclosure statement is being filed after the mailing of a first Office Action on the merits, but before the mailing date of any of a Final Office Action under

§ 1.113, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution in the application.


**CERTIFICATION UNDER 37 C.F.R. § 1.97(e)**


The undersigned hereby certifies:

that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Acknowledgment of receipt is respectfully requested.

Respectfully submitted,

By:   
Nancy T. Morris, Reg. No. 42,017  
STINSON MORRISON HECKER LLP  
1201 Walnut Street, Suite 2800  
Kansas City, MO 64106-2150  
Telephone: (816) 842-8600  
Facsimile: (816) 691-3495  
Attorney for Applicant



(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

<b>Application Number:</b>	10/053,669
<b>Filing Date:</b>	January 24, 2002
<b>First Named Inventor:</b>	Ibert C. Wells
<b>Group Art Unit:</b>	1644
<b>Examiner Name:</b>	Szperka, Michael Edward
<b>Attorney Docket Number:</b>	N1427-0005 (800812-0004)

[illegible][illegible]Date  
Considered

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO (Modified) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number:	10/053,669
				Filing Date:	January 24, 2002
				First Named Inventor:	Ibert C. Wells
				Group Art Unit:	1644
				Examiner Name:	Szperka, Michael Edward
Sheet	2	of	2	Attorney Docket Number:	N1427-0005 (800812-0004)

**OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS AND INFORMATION**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		MORI, KAZUO, et al. Decreases in Substance P and Vasoactive Intestinal Peptide Concentrations in Plasma of Stroke-Prone Spontaneously Hypertensive Rats. Jpn. Heart J. 1993, 34:785-794.	
		SANFILIPPO, JOSEPH S., et al. Amniotic Fluid Levels of Substance P. J. Reprod. Med. 1992, 37:733-736	
		FAULHABER, H.D., et al. Substance P in Human Essential Hypertension. J. Cardiovascular Pharmacology 1987, 10(Suppl. 12):S172-S176.	
		PAGE, N.M., et al. Excessive Placental Secretion of Neurokinin B During the Third Trimester Causes Pre-eclampsia. Nature 2000, 405:797-800.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.